Population Pharmacokinetics of Blinatumomab in Pediatric and Adult Patients with Hematological Malignancies

BACKGROUND AND OBJECTIVES: Blinatumomab (BLINCYTO(®)) is a novel bispecific T cell engager (BiTE(®)) approved in the USA for the treatment of relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL) in children and adults, as well as minimal residual disease ALL in adults. This ana...

Descripción completa

Detalles Bibliográficos
Autores principales: Clements, John David, Zhu, Min, Kuchimanchi, Mita, Terminello, Bianca, Doshi, Sameer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7109194/
https://www.ncbi.nlm.nih.gov/pubmed/31679130
http://dx.doi.org/10.1007/s40262-019-00823-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7109194/
https://www.ncbi.nlm.nih.gov/pubmed/31679130
http://dx.doi.org/10.1007/s40262-019-00823-8

Ejemplares similares